|
|
|
|
Insulin study could lead to new dosage devices
Buy Maxalt Without a Prescription Buy no Prescription Strattera Order Tamiflu no Prescription Online Buy Medrol Without a Prescription Buy Naltrexone Without a Prescription Buy no Prescription Antabuse Online Buy Boniva no Prescription Buy Propecia Without a...
|
|
|
NICE requests more data on AstraZeneca's Iressa for NSC lung cancer, notably on cost effectiveness
requests more data on AstraZeneca's Iressa for NSC lung cancer, notably on cost effectiveness - Pharmaceutical and News - Pharma Letter You are not logged in Keywords: UK, AstraZeneca, NICE, Iressa, Lung cancer, Related 20 August 200918 August 20096...
|
|
|
Gefitinib patient access scheme may cost more, NICE says
By Newsteam AstraZenecas patient access scheme for anticancer drug gefitinib (Iressa) has come under fire in National Institute for Health and Clinical Excellence issued today (29 January 2010).Under the scheme, which was proposed last September, a...
|
|
|
UK's NICE wants more data on cancer drug Iressa
* Cost agency says needs more data before deciding on Iressa * AstraZeneca drug approved in EU for certain lung cancers LONDON, Jan 29 (Reuters) - Britain's healthcare cost-effectiveness watchdog said it needed more data before deciding whether...
|
|
|
NICE wants more data on cancer drug Iressa
LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog said it needed more data before deciding whether AstraZeneca Plc's cancer drug Iressa can be offered on the state-run National Health Service.The National Institute for Health and...
|
|
|
AstraZeneca hands global oncology portfolio to Edelman
Edelman has picked up a lucrative account with AstraZeneca to handle its entire global oncology portfolio.The agency won the brief following a two-way shoot-out against Cohn & Wolfe. Industry sources suggested the account could be worth up to 500,000....
|
|
|
Lung Cancer in Never-Smokers: Molecular Factors Trump Risk Factors
While they represent a minority of patients with lung cancer, more than 20,000 people in the United States who never smoked cigarettes are diagnosed with lung cancer each year.[1] This makes lung cancer in never-smokers one of the 10 most common cancersmore...
|
|
|
Pfizer's Great Data Won't Do Much
Recs 0 //Create your sharelet with desired properties and set button element to false object //Tie customized button to This button functionality.element Disney Buys Marvel! David Gardner called it! Hes up 1,334%! See what Davids recommending that you...
|
|
|
Pfizer's Great Data Won't Do Much
The full data from a clinical trial testing Pfizer's (NYSE: PFE) Sutent in pancreatic cancer was truly amazing.The drug more than doubled the time it took for the tumor to start growing again, and Sutent also improved survival of the patients.
|
|
|
Some Non-small Cell Lung Cancers may be Treated by Combination Therapy
Dana-Farber Cancer Institute and Massachusetts General Hospital (MGH) Cancer Center scientists have said that even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that...
|
|
|
Combo Therapy May Be Effective Against Some Non-Small Cell Lung Cancers
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and...
|
|
|
Combination treatment strategies may benefit patients with non-small cell lung cancer
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and...
|
|
|
Combo Therapy May be Effective Against Some Non-Small Cell Lung Cancers
Source: Dana-Farber Cancer Institute Newswise Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth...
|
|
|
Combating Non-Small Cell Lung Cancers With Combo Therapy
Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and...
|
|
|
Combination therapy may be effective against some non-small cell lung cancers
ScienceDaily (Jan.19, 2010) Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber...
|
|
|
Combination therapy may be effective against some non-small cell lung cancers
BOSTONEven when their tumors are shrinking in response to therapy, some non-small cell lung cancer (NSCLC) patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth, Dana-Farber Cancer Institute and...
|
|
|
Combination therapy may be effective against some non-small cell lung cancers
IMAGE:This is an EGFR mutant non-small cell lung cancer harboring a small population of drug resistant cells (red) prior to drug exposure.These cells contain an amplification of MET. BOSTONEven when their tumors are shrinking in response to therapy, some...
|
|
|
Combination therapy may be effective against some non-small cell lung cancers
IMAGE:This is an EGFR mutant non-small cell lung cancer harboring a small population of drug resistant cells (red) prior to drug exposure.These cells contain an amplification of MET. BOSTONEven when their tumors are shrinking in response to therapy, some...
|
|
|
AstraZeneca continues personalised healthcare push
AstraZeneca and cancer diagnostics specialist Dako Denmark are to develop companion diagnostics for a number of the pharma company's oncology projects, including biologics and small molecules.The tests will then be used by doctors to help determine the most...
|
|
|
AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
LONDON (Logo: , http://www.newscom.com/cgi-bin/prnh/20100118/PH38535LOGO ) (Logo: , http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) Under the agreement, the companies will work together to develop diagnostic tests to help physicians determine the...
|
|
|
AACR-IASLC: Second Shot at EGFR Drug Therapy Often Effective
Note that this study focused on gefitinib, which is not currently FDA approved for treatment of lung cancer, but that the findings may be generalizable to the similar compound erlotinib, which is.Note that this study was published as an abstract and...
|
|
|
ASCO Issues Annual Progress Report on Top Cancer Research Advances
The American Society of Clinical Oncology (ASCO) released its report, Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening, an independent assessment of the most significant clinical cancer research studies of the...
|
|
|
Strides Made in Lung Cancer Treatment
WEDNESDAY, Jan.13 (HealthDay News) -- Advances in genetics and biomarker identification and testing are finally bearing fruit in the battle against lung cancer, a new set of studies suggests. Until now, lung cancer has lagged behind other malignancies when...
|
|
|
Strides made in lung cancer treatment
WEDNESDAY, Jan.13 (HealthDay News) -- Advances in genetics and biomarker identification and testing are finally bearing fruit in the battle against lung cancer, a new set of studies suggests. Until now, lung cancer has lagged behind other malignancies when...
|
|
|
Strides made in lung cancer treatment
By Amanda Gardner HealthDay Reporter WEDNESDAY, Jan.13 (HealthDay News) -- Advances in genetics and biomarker identification and testing are finally bearing fruit in the battle against lung cancer, a new set of studies suggests. Until now, lung cancer has...
|
